RUNX1 and acute myeloid leukemia: Our hypothesis was that CG-SH cells would efficiently engraft immune-deficient mice and demonstrate residual disease after anthracycline/cytarabine-based chemotherapy, rendering it a robust, in vivo platform to study mechanisms of chemotherapy resistance and novel therapeutic approaches in CN-AML harboring RUNX1 mutations.